Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-44

Very important...ATL is applicable to all boys with DMD.

Sarepta's drug is only applicable to 13% of DMD boys.

Mark Diamond, CEO of Antisense Therapeutics said: “Given that there is currently no effective treatment for non-ambulant DMD patients, we are particularly encouraged by the preliminary data from the first six patients in this trial, which suggests a positive drug effect and may also demonstrate a meaningful slowing of disease progression compared to what might otherwise have been expected....

Lets all say it slowly: "...slowing of disease progression..."

.